An Open Label Study of Sirolimus as Primary Therapy for the Treatment of Chronic GVHD Following Allogeneic Bone Marrow Transplant

Evaluate the clinical activity of sirolimus in combination with cyclosporine and corticosteroids as first line therapy for the treatment of chronic Graft Versus Host Disease.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • procedure : high dose chemotherapy and autologous hematopoietic cell transplant

Phase: Phase 2


Ages Eligible For Study:

18 Years - 70 Years

Inclusion Criteria

- active chronic GvHD - ANC > 1000/mm^3 - therapeutic cyclosporine

External Links

Explore related trials

Contact information

Primary Contact:

BMT Referrals 6507230822

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: